News | Congenital Heart | October 24, 2019

University of Arizona Leads Statewide Study of Congenital Heart Defects

The University of Arizona Division of Pediatric Cardiology Congenital Heart Program will explore the public health problem of congenital heart defects among children, adolescents and adults through a five-year project

University of Arizona Leads Statewide Study of Congenital Heart Defects

October 24, 2019 — Investigators at the University of Arizona Steele Children's Research Center are leading a statewide study as part of a national effort to conduct population-based surveillance of congenital heart defects across the life span, thanks to funding from the U.S. Centers for Disease Control and Prevention (CDC).

Jennifer Andrews, Ph.D., an assistant professor in the Department of Pediatrics and a member of the UA Steele Children's Research Center, has received $2.4 million through a five-year CDC cooperative agreement. Under the agreement, she will examine survival, healthcare utilization, other health conditions and outcomes over time for a variety of geographically, culturally and socioeconomically challenged subpopulations of Arizona children, adolescents and adults living with congenital heart defects.

In 2012, the CDC started expanding enhanced public health tracking of congenital heart defects to include children, adolescents and adults. This project seeks to better understand the survival, healthcare use and longer-term outcomes of individuals born with congenital heart defects across their life span. Understanding these health issues and needs at all ages is vital to improve the lives of individuals living with congenital heart disease, Andrews said.   

An estimated 40,000 children are born with a heart problem each year, 25 percent of whom will have a critical heart condition requiring surgery during the first year of life. Treatment advances have changed the natural history of congenital heart disease; today, most infants born with a critical congenital heart condition are expected to live into adolescence and adulthood, but little is known about their outcomes.

"This project will establish a much-needed understanding of the scope of congenital heart defects, a complex set of conditions that afflict more than 2.4 million people in the United States," said UA President Robert C. Robbins, M.D. "Thanks to progress from collaborative pediatric cardiology and cardiothoracic surgery teams, such as the one at the UA College of Medicine – Tucson, young people born with complex heart conditions are more likely than ever to grow up to be adults with fulfilling lives. Yet more than half of all those who are afflicted with congenital heart disease are adults, and by monitoring and treating throughout the life span, we will better understand how to help individuals of all ages."

This cooperative agreement will expand the research program within the Division of Pediatric and Congenital Cardiology, led by Scott Klewer, M.D., professor of pediatrics, medicine and cellular and molecular medicine at the College of Medicine – Tucson. Andrews is director of research for the Congenital Heart Program. She and Klewer also are members of the UA Sarver Heart Center. Klewer holds the UA Sarver Heart Center Peggy M. Barrett Endowed Chair for Congenital Heart Disease in Adults.

For more information: www.peds.arizona.edu/steele

Related Content

The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

News | Cardiovascular Clinical Studies | January 20, 2020
January 20, 2020 — Scientists at Los Alamos and international partners have created the first 3-D images of a special
Top Cardiology New in 2019 From the European Society of Cardioloigy (ESC)
News | Cardiovascular Clinical Studies | December 23, 2019
Environmental and lifestyle issues were popular this year, with pick up from both...
News | Cardiovascular Clinical Studies | November 26, 2019
November 26, 2019 — The University of Connecticut (UConn) Department of Kinesiology and Hartford Healthcare have sele
FDA Issues Final Guidance on Live Case Presentations During IDE Clinical Trials
News | Cardiovascular Clinical Studies | July 10, 2019
The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During Investigational...
Veradigm Partners With American College of Cardiology on Next-generation Research Registries
News | Cardiovascular Clinical Studies | July 03, 2019
The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to power the next...
New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Overlay Init